D-0615-2017 Class II Terminated

Recalled by Claris Lifesciences Inc — North Brunswick, NJ

FDA drug recall D-0615-2017 was initiated by Claris Lifesciences Inc on Mar 10, 2017 and is designated Class II. Reason for recall: Lack of Assurance of Sterility: there is potential of a leak from the primary container which may result in a potential breach of sterility and contamination of the product. The recall status is terminated (terminated Sep 18, 2020). Affected quantity: 24,456 units (1019 cartons x 24 bags).

Recall details

Product Type
Drugs
Report Date
Apr 5, 2017
Initiation Date
Mar 10, 2017
Termination Date
Sep 18, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
24,456 units (1019 cartons x 24 bags)

Product description

Levofloxacin Injection in 5% Dextrose, 750 mg in 150 mL 5% Dextrose, Rx only, Manufactured for: Claris Lifesciences Inc. North Brunswick NJ, 08902, By: Claris Injectable Ltd. Gujarat, India, NDC 36000-048-24

Reason for recall

Lack of Assurance of Sterility: there is potential of a leak from the primary container which may result in a potential breach of sterility and contamination of the product.

Distribution pattern

Nationwide

Code information

Lot #: A060040, Exp. Dec 2017

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0615-2017
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0615-2017. Report a data issue: hello@regdatalab.com.